EP4739291A2 - Verabreichung von keratolytika an augen- und periokulare oberflächen - Google Patents

Verabreichung von keratolytika an augen- und periokulare oberflächen

Info

Publication number
EP4739291A2
EP4739291A2 EP24838954.6A EP24838954A EP4739291A2 EP 4739291 A2 EP4739291 A2 EP 4739291A2 EP 24838954 A EP24838954 A EP 24838954A EP 4739291 A2 EP4739291 A2 EP 4739291A2
Authority
EP
European Patent Office
Prior art keywords
pharmaceutical composition
individual
eye
finger
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP24838954.6A
Other languages
English (en)
French (fr)
Inventor
Charles Bosworth
Yair Alster
Omer Rafaeli
Hila Epstein-Barash
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Azura Ophthalmics Ltd
Original Assignee
Azura Ophthalmics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Azura Ophthalmics Ltd filed Critical Azura Ophthalmics Ltd
Publication of EP4739291A2 publication Critical patent/EP4739291A2/de
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP24838954.6A 2023-07-07 2024-07-05 Verabreichung von keratolytika an augen- und periokulare oberflächen Pending EP4739291A2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363525551P 2023-07-07 2023-07-07
PCT/IB2024/000366 WO2025012701A2 (en) 2023-07-07 2024-07-05 Administration of keratolytics to ocular and periocular surfaces

Publications (1)

Publication Number Publication Date
EP4739291A2 true EP4739291A2 (de) 2026-05-13

Family

ID=94216246

Family Applications (1)

Application Number Title Priority Date Filing Date
EP24838954.6A Pending EP4739291A2 (de) 2023-07-07 2024-07-05 Verabreichung von keratolytika an augen- und periokulare oberflächen

Country Status (2)

Country Link
EP (1) EP4739291A2 (de)
WO (1) WO2025012701A2 (de)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9463201B2 (en) * 2014-10-19 2016-10-11 M.G. Therapeutics Ltd Compositions and methods for the treatment of meibomian gland dysfunction
AU2017250509B2 (en) * 2016-04-14 2023-03-02 Azura Ophthalmics Ltd. Selenium disulfide compositions for use in treating meibomian gland dysfunction
CN114980957A (zh) * 2019-11-04 2022-08-30 阿祖拉眼科有限公司 针对眼内或眼周病症的计量剂量
WO2021140417A2 (en) * 2020-01-10 2021-07-15 Azura Ophthalmics Ltd. Instructions for composition and sensitivity

Also Published As

Publication number Publication date
WO2025012701A2 (en) 2025-01-16
WO2025012701A3 (en) 2025-02-13

Similar Documents

Publication Publication Date Title
US11013749B2 (en) Compositions and methods for the treatment of meibomian gland dysfunction
US20050059639A1 (en) Ophthalmic compositions and method for treating eye discomfort and pain
JP2019532931A (ja) 眼瞼炎の治療に使用するための医薬組成物
US12083147B2 (en) Compositions and methods for the treatment of contact lens discomfort
CN117298073B (zh) 一种用于治疗干眼症的经皮给药的药物组合物
Leibowitz et al. Gel tears: a new medication for the treatment of dry eyes
US20250041212A1 (en) Compositions and methods for the treatment of anterior blepharitis and posterior blepharitis
WO2025012701A2 (en) Administration of keratolytics to ocular and periocular surfaces
US20240285679A1 (en) Compositions and methods for vision improvement
US20250262331A1 (en) Composition and methods for improving signs and symptoms of ocular disorders
WO2025012700A2 (en) Compositions and methods for the treatment of autoimmune disorders
WO2024100454A2 (en) Composition and methods for improving signs and symptoms of ocular disorders
TW202426011A (zh) 用於視力改善之組合物及方法
WO2024240216A9 (zh) 一种有效延缓及治疗近视的药物组合物
HK40109101A (zh) 一种有效延缓及治疗近视的药物组合物
HK1238496B (zh) 用於治疗睑板腺功能障碍的组合物和方法

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20260116

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR